IL6 and COVID-19: Despite the fact that immunosuppressive-drugs are generally not recommended during viral infections (Russell et al., 2020), tocilizumab has been tested in COVID-19 patients with elevated IL-6 levels, and exhibited several beneficial effects (Witkowski et al., 2016; Moll et al., 2019).